Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al
- PMID: 27477123
- DOI: 10.1016/j.clon.2016.07.004
Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al
Comment on
-
High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.Clin Oncol (R Coll Radiol). 2016 Sep;28(9):611. doi: 10.1016/j.clon.2016.03.006. Epub 2016 May 4. Clin Oncol (R Coll Radiol). 2016. PMID: 27131755 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical